Alluvi, previously BI 4744, presents a notable development in weight loss therapy. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/